Key Points Over time, Medtronic's business got bloated, and growth slowed. The medical device giant overhauled its business and is starting to see stronger results. Wall Street doesn't seem to care about Medtonic's business upturn. 10 stocks we like better than Medtronic › Wall Street is a fickle place, with investor emotions often shifting quickly. But sometimes, somewhat ironically, investor opinions are stubbornly hard to change. That's likely what's behind Jim Cramer's description of Medtronic (NYSE: MDT) as a "quandary." Here's the backstory and why long-term dividend investors may want to reevaluate their opinion of this medical device giant right now.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.
